Skip to main content
MindWalk Holdings Corp. logo

MindWalk Holdings Corp. — Investor Relations & Filings

Ticker · HYFT ISIN · CA45257F2008 US Professional, scientific and technical activities
Open in API
Filings indexed 256 across all filing types
Latest filing 2021-03-18 Regulatory Filings
Country US United States of America
Listing US HYFT

About MindWalk Holdings Corp.

https://www.ipatherapeutics.com/

MindWalk Holdings Corp. is a Bio-Native AI company that focuses on transforming drug discovery and development. The company operates a biointelligence ecosystem that integrates artificial intelligence, multi-omics data, and advanced laboratory research to make complex biology computable and actionable. This unified platform is designed to accelerate the discovery and development of biologics, including therapeutic antibodies, diagnostics, vaccines, and peptide therapeutics, from target identification through to the clinical stage. Its capabilities are powered by proprietary technologies such as the patented HYFT® technology and the LensAI™ platform, which are adaptable to specific targets, modalities, and program priorities.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign issuer filed with the SEC. It includes references to exhibits such as Management's Discussion and Analysis (MDA) and Condensed Interim Consolidated Financial Statements for the three and nine months ended January 31, 2021 and 2020. However, the document itself is only 1982 characters long and primarily serves as a cover report referencing these exhibits rather than containing the full financial statements or detailed analysis. It also includes CEO and CFO certifications. According to the rules, if a document is short and references reports or certifications without containing substantive financial data, it should be classified as a Regulatory Filing (RNS). Therefore, this document is best classified as a Regulatory Filing (RNS).
2021-03-18 English
IMMUNOPRECISE ANTIBODIES LTD. FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes metadata about the filing, the issuer's address, and a reference to an exhibit (a press release dated March 17, 2021). The document is short (1396 characters) and does not contain detailed financial statements or substantive financial data. It primarily serves as a regulatory filing to report information to the SEC, typical of Form 6-K submissions. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories.
2021-03-18 English
IMMUNOPRECISE ANTIBODIES LTD. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1391 characters), and it primarily serves as a regulatory filing to report information between annual reports. According to the rules, such filings that do not fit other categories and are primarily regulatory submissions should be classified as Regulatory Filings (RNS).
2021-03-16 English
IMMUNOPRECISE ANTIBODIES LTD. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1391 characters), and it primarily serves as a regulatory filing to report current information rather than a full financial report or earnings release. According to the rules, Form 6-K filings are best classified under Regulatory Filings (RNS) as they are general regulatory announcements and do not fit into other specific categories like Annual Report or Interim Report.
2021-03-04 English
IMMUNOPRECISE ANTIBODIES LTD. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1397 characters), and it primarily serves as a regulatory filing to report information to the SEC. According to the rules, Form 6-K filings are best classified under Regulatory Filings (RNS) as they are general regulatory announcements and do not fit into other specific categories like Annual Report or Interim Report. Therefore, the appropriate classification is RNS with high confidence.
2021-02-19 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It includes an exhibit index referencing a news release dated February 10, 2021, but the document itself is short (1319 characters) and does not contain detailed financial statements or substantive financial data. It is primarily an announcement/report filing rather than a full financial report. According to the rules, such filings that do not fit other categories and are brief are best classified as Regulatory Filings (RNS).
2021-02-11 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.